VANCOUVER, BRITISH COLUMBIA--(CCNMatthews - May 9, 2007) - WEX Pharmaceuticals Inc. (TSX:WXI) (“WEX” or the “Company”) is pleased to announce that further to the Company’s news release dated September 6, 2006 with regard to the resumption of the clinical development of TectinTM in the target indication malignant cancer pain, the Company has filed a Clinical Trial Application (CTA) with the Biologics and Genetics Therapies Directorate (BGTD) of Health Canada for TectinTM, lead candidate in the Company’s Tetrodotoxin (TTX) technology platform. According to current regulations, the BGTD has a 30-day default period to review the application. Upon clearance from Health Canada, WEX will initiate the clinical trial of TectinTM for the treatment of moderate to severe inadequately controlled cancer-related pain.
